RecruitingNCT02257866
Immune
Takayasu Arteritis
Also known as pulseless disease, aortic arch syndrome, Takayasu disease
Takayasu Arteritis is a chronic granulomatous vasculitis predominantly affecting the aorta and its major branches, causing transmural inflammation that leads to stenosis, occlusion, or aneurysm formation with resulting limb and organ ischem
ORPHA:3287 ↗Prevalence 1-2 in 1,000,000 in Western countries; higher in East AsiaOnset Young adulthood; predominantly women aged 10-40Large vessel granulomatous vasculitis
19
studies recruiting now
as of 7 Sept 2026
80
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
30 Apr 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT07087912
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
RecruitingNCT07077304
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
RecruitingNCT07558382
Global Initiative on Takayasu Arteritis (GITA)
RecruitingNot applicableNCT07491913
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 19 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Takayasu Arteritis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: A.R.T.A. Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Takayasu Arteritis
Takayasu Arteritis is a chronic granulomatous vasculitis predominantly affecting the aorta and its major branches, causing transmural inflammation that leads to stenosis, occlusion, or aneurysm formation with resulting limb and organ ischemia. The disease disproportionately affects young women, particularly of Asian descent, and follows a biphasic course with an early inflammatory phase and a later fibrotic obliterative phase in which vascular damage may progress despite suppressed systemic inflammation. Biological therapies targeting IL-6 and TNF have emerged as important steroid-sparing agents in refractory disease.
Common clinical features
Absent or diminished upper limb pulses with blood pressure discrepancyLimb claudication (arm and leg)Hypertension from renal artery stenosisCarotidynia and neck painVisual disturbances and retinal ischemiaConstitutional symptoms (fever, weight loss, fatigue) in active phaseAortic regurgitation and heart failure from aortic root involvement
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
10 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Prednisolone (Cortalone)
Phase 3Ustekinumab (Stelara)
Phase 3Upadacitinib (Upadacitinib component of abbv-599)
Phase 3Azathioprine (Azamune)
Phase 3Tocilizumab (Actemra roactemra)
Phase 3Mycophenolate Mofetil (Arzip)
Phase 2/3Cyclophosphamide (Cyclophosphamide)
Phase 2/3Prednisone (Cortan)
+ 2 more in development
Before you apply
Things trial teams commonly ask about for Takayasu Arteritis. Not eligibility rules; those are set by each study.
- Disease activity assessment using NIH or ITAS criteria is required for most trials; imaging confirmation (MR or CT angiography, PET-CT) of active vessel inflammation is typically mandatory at screening
- IL-6 inhibitor trials (tocilizumab) require documented inadequate response to corticosteroids; compile steroid dose history, duration, and relapse pattern
- Renal function impairment from renovascular hypertension can affect drug dosing eligibility; provide recent estimated GFR and renal imaging results
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).